Personalized electrical stimulation for drug-resistant epilepsy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of personalized transcranial direct current stimulation (tDCS) in reducing seizure frequency in patients with drug-resistant focal epilepsy. Participants will be randomly assigned to receive either active tDCS or sham stimulation over a period of 10 days, with sessions consisting of two 20-minute stimulation periods each day. The study will also assess changes in quality of life, the incidence of side effects, and epilepsy severity scores. The goal is to determine if this innovative approach can provide significant benefits compared to standard care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patient, parents or legal representative who have given written informed consent;
2. Age: ≥ 9 years;
3. Patients with drug-resistant focal epilepsy with no evolutive brain lesion and no surgical indication or with a previous surgical failure, refusing surgery or with a planned surgery compatible with the total duration of this study;
4. SEEG previously performed before inclusion with an adequate definition of the epileptogenic zone with all data required (pre-SEEG MRI, CT-scan or MRI with electrodes during SEEG and SEEG files) for personalization ;
5. Patient having a pre-SEEG 3D-T1 MRI and CT-scan with electrodes during SEEG available; This MRI can be done specifically for this trial or might be reused from EPINOV or NEURO7T trial)
6. For patients with VNS, experiencing no response or partial response, and for whom the stimulation parameters have been stable for at least 6 months
7. A research MRI scan that is suitable for navigated brain stimulation (NBS) and generation of electrical fields including dMRI for tractography;
8. Number of seizures ≥3/month during the baseline (before the first session of tDCS treatment);
9. Patient having stable medications for epilepsy 4 weeks before the baseline (except rescue treatment);
10. Patient's IQ, which in the investigator's opinion will enable questionnaires and neuropsychological assessments to be carried out;
11. Patient able to understand, speak and write in French;
12. Patient able to follow study's procedure;
13. Patient beneficiary or affiliated to a health insurance plan.

Exclusion Criteria:

1. Patients with seizures of generalized onset in the last 12 months;
2. Patient with multifocal epileptogenic zones, bilateral epileptogenic zone, or poorly defined epileptogenic zone. The epileptogenic network should not be restricted to the orbito frontal cortex or cingulate cortex;
3. Patients with psychogenic nonepileptic seizures;
4. Patient presenting a contraindication to MRI 3T (patient having a pacemaker, metallic foreign bodies, non-removably implanted electronic medical devices, claustrophobia, inability to remain in supine position, vagus nerve stimulator even when switched off is a contraindication for MRI 3T. EPINOV or NEURO 7T trial patients, who have accepted for their data to be reused, can be included even while wearing a VNS device) ;
5. Substance use abuse that may include alcohol , opioids (heroin, fentanyl) stimulants (Cocaine, methamphetamine) , hallucinogens (LSD, psilocybin (magic mushrooms), MDMA (Ecstasy))
6. Patient presenting a serious intercurrent pathology and/or a progressive brain tumor
7. Patient having damaged skin or scalp that may interfere with tDCS stimulation (e.g., eczema, lesion);
8. Patient having any cranial metal implants such as shrapnel or surgical clips (excluding \<1 mm thick epicranial titanium skull plates and dental fillings) or medical devices (i.e. cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant)
9. Patient having previous surgeries opening the skull leaving skull defects capable of allowing the insertion of a cylinder with a radius greater or equal to 5 mm;
10. Any condition that makes the study subject, in the opinion of the investigator, unsuitable for the study including presence of any disease, abnormality, medical or physical condition that, in the opinion of the investigator, may adversely impact, compromise, interfere, limit, affect or reduce the safety of the subject, the integrity of the data ;
11. Person protected by articles L1121-5, L1121-6 of Public Health Code (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations of social fragility, adults unable or unable to express their consent, person under judicial safeguard (article L1122-2)).

Where it's running

• Service de Neurophysiologie Clinique de l'Enfant et de L'Adulte, Pôle de Neurosciences Cliniques
  Bordeaux, France Recruiting
• Département Neurologie Fonctionnelle et Epilepsie, Hôpital neurologique - Hospices Civils de Lyon
  Bron, France Recruiting
• Service Epileptologie et Rythmologie Cérébrale, Hôpital La Timone
  Marseille, France Recruiting
• Service de Neurophysiologie clinique - Hôpital Roger Salengro, CHU Lille
  Lille, France Not yet recruiting
• Service de Neurophysiologie clinique - GHU Psychiatrie et Neurosciences Sainte-Anne
  Paris, France Not yet recruiting
• Service de Neurologie - CHU de Rennes - Hôpital Pontchaillou
  Rennes, France Not yet recruiting

Study contacts

• Study coordinator: Fabrice Bartolomei, MD, PhD
• Email: fabrice.bartolomei@ap-hpm.fr
• Phone: 0491384990

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy

  This study tests whether low intensity focused ultrasound can help reduce seizures in adults with drug‑resistant epilepsy.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07680842

• PET‑MRI mapping of brainstem serotonin pathways in adults with Dravet syndrome

  This uses a PET‑MRI scan with the tracer [18F]MPPF to see if serotonin pathways in the brainstem differ in adults with Dravet syndrome compared with healthy controls.

  Recruiting Hospices Civils de Lyon · Bron, Rhone · NCT07013331

• Gut–brain microbiota link in new‑onset and drug‑resistant epilepsy

  This project will see if gut bacteria and their chemical products are linked to how well people with new‑onset or drug‑resistant epilepsy do after surgery, vagus‑nerve stimulation, or a ketogenic diet.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07010445

• Evaluating a new ultrasound treatment for drug-resistant epilepsy

  This study is testing a new ultrasound treatment for people with drug-resistant epilepsy to see if it can help reduce their seizures and improve their quality of life.

  Recruiting NaviFUS Corporation · Taipei · NCT06492720

• Low-intensity focused ultrasound treatment for drug-resistant epilepsy

  This study is testing if low-intensity focused ultrasound can help people with drug-resistant temporal lobe epilepsy have fewer seizures while they continue taking their regular medications.

  Recruiting at 3 sites Phase 1/2 NaviFUS Corporation · Palo Alto, California and 2 other locations · NCT06388707

• Mapping social cognition in epilepsy patients

  This study is trying to see how epilepsy affects social thinking by comparing brain scans and tests of social skills in people with epilepsy and healthy individuals before and after surgery.

  Recruiting Assistance Publique - Hôpitaux de Paris · Gif-sur-Yvette and 1 other locations · NCT05527093

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.